Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Urogen Pharma (URGN : NSDQ)

• Company Description    UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. Number of Employees: 235

• Price / Volume Information    Yesterday's Closing Price: $18.79 Daily Weekly Monthly 20 Day Moving Average: 1,075,705 shares Shares Outstanding: 46.26 (millions) Market Capitalization: $869.30 (millions) Beta: 1.10 52 Week High: $21.71 52 Week Low: $3.42 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.42% -8.07% 12 Week 26.36% 14.78% Year To Date 76.43% 61.38%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 400 Alexander Park Drive - Princeton,NJ 08540 USA ph: 646-768-9780 fax: - vincent.perrone@urogen.com http://www.urogen.com

• General Corporate Information    Officers Elizabeth Barrett - Chief Executive Officer and President Arie Belldegrun - Chairman Chris Degnan - Chief Financial Officer Cynthia Butitta - Director Leana S. Wen - Director Peer Information Urogen Pharma (CORR.) Urogen Pharma (RSPI) Urogen Pharma (CGXP) Urogen Pharma (BGEN) Urogen Pharma (GTBP) Urogen Pharma (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: M96088105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 46.26 Most Recent Split Date: (:1) Beta: 1.10 Market Capitalization: $869.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.66 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.06 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 9.22 EPS Growth vs. Year Ago Period: -15.38% vs. Previous Quarter: -14.13% Sales Growth vs. Year Ago Period: 10.83% vs. Previous Quarter: 19.56% ROE 06/30/25 - - 03/31/25 - -97,487.15 12/31/24 - -7,363.55 ROA 06/30/25 - -59.38 03/31/25 - -49.57 12/31/24 - -47.43 Current Ratio 06/30/25 - 4.14 03/31/25 - 5.65 12/31/24 - 6.01 Quick Ratio 06/30/25 - 3.99 03/31/25 - 5.47 12/31/24 - 5.81 Operating Margin 06/30/25 - -164.44 03/31/25 - -150.68 12/31/24 - -140.35 Net Margin 06/30/25 - -164.44 03/31/25 - -150.68 12/31/24 - -140.35 Pre-Tax Margin 06/30/25 - -160.04 03/31/25 - -147.23 12/31/24 - -137.22 Book Value 06/30/25 - -2.02 03/31/25 - -1.01 12/31/24 - -0.21 Inventory Turnover 06/30/25 - 1.37 03/31/25 - 1.19 12/31/24 - 1.13 Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©